<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017987</url>
  </required_header>
  <id_info>
    <org_study_id>ATB-101-002</org_study_id>
    <nct_id>NCT05017987</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012</brief_title>
  <official_title>A Phase I Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autotelicbio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autotelicbio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and evaluate safety and pharmacokinetic Characteristics after administration of&#xD;
      ATB-101 or co-administration of ATB-1011 and ATB-1012 in fasted Healthy Adult Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic endpoints&#xD;
&#xD;
        1. Primary endpoint : AUCt, Cmax of Dapagliflozin, Olmesartan&#xD;
&#xD;
        2. Secondary endpoint : AUC∞, Tmax, t1/2, CL/F, Vd/F of Dapagliflozin, Olmesartan&#xD;
&#xD;
      Safety evaluation&#xD;
&#xD;
        1. Adverse reactions (but only in case of TEAE)&#xD;
&#xD;
        2. Concomitant drugs&#xD;
&#xD;
        3. Vital signs&#xD;
&#xD;
        4. Laboratory test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2021</start_date>
  <completion_date type="Actual">July 12, 2021</completion_date>
  <primary_completion_date type="Actual">July 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open, Randomization, single oral administration, 2 Intervention group, crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Maximum concentration of drug in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Maximum concentration of drug in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC∞ of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Area under the plasma drug concentration-time curve from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Apparent total clearance of the drug from plasma after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Olmesartan</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Apparent volume of distribution after non-intravenous administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞ of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Area under the plasma drug concentration-time curve from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Apparent total clearance of the drug from plasma after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Dapagliflozin</measure>
    <time_frame>Day1(first stage), Day8(scond stage)</time_frame>
    <description>Apparent volume of distribution after non-intravenous administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence A=Reference-Test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T(Test drug): ATB-101 R1(Reference drug1): ATB-1011 R2(Reference drug2): ATB-1012&#xD;
First stage: co-administration of R1 and R2, single dose and then Washout: 7days and then Second stage: administration of T, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B=Test-Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First stage: administration of T, single dose and then Washout: 7days and then Second stage: co-administration of R1 and R2, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATB-101, ATB-1011, ATB-1012</intervention_name>
    <description>Test drug&#xD;
- Code name: ATB-101&#xD;
Control drug1&#xD;
Code name: ATB-1011&#xD;
Active ingredient: Olmesartan&#xD;
Control drug2&#xD;
Code name: ATB-1012&#xD;
Active ingredient: Dapagliflozin</description>
    <arm_group_label>Sequence A=Reference-Test</arm_group_label>
    <arm_group_label>Sequence B=Test-Reference</arm_group_label>
    <other_name>ATB-1011 brand name: Olmetec</other_name>
    <other_name>ATB-1012 brand name: Forxiga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those who are over 19 years old at the screening visit&#xD;
&#xD;
          -  Those who do not have clinically significant congenital or chronic diseases and have&#xD;
             no pathological symptoms or findings upon medical examination at the screening visit&#xD;
&#xD;
          -  Those who determined as suitable study subjects by the principal investigator&#xD;
&#xD;
          -  A person who signs the consent form at will, after hearing and understanding a&#xD;
             sufficient explanation of the purpose, contents, characteristics of the&#xD;
             investigational product, and expected adverse reactions of this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have a clinically significant disease or have a history of such disease&#xD;
&#xD;
          -  Those who have a history of gastrointestinal surgery&#xD;
&#xD;
          -  Those who have taken drugs that induce and inhibit metabolism enzymes such as barbital&#xD;
             drugs&#xD;
&#xD;
          -  Those who participated in other clinical trials or bioequivalence studies and&#xD;
             administered the investigational products within 6 months of the first administration&#xD;
             date.&#xD;
&#xD;
          -  Those who donated whole blood within 2 months or donated components within 2 weeks, or&#xD;
             received a blood transfusion within 1 month of the first administration date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaewoo Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>H + Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gwanak-gu</state>
        <zip>08779</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

